Partner Headlines - BIIB

  1. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  2. Broad Indexes Little Changed; Facebook Breaks Out

    IBD
  3. Stocks Struggle To Hold Gains; Alaska Air, Spirit Up

    IBD
  4. Morning Market Losers

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. Stocks Press Higher; Biotechs Gilead, Biogen Rise

    IBD
  7. Roche Drugs For Alzheimer's, Breast Cancer Disappoint

    IBD
  8. Juiced By Fed, Stocks Rocket Higher; Biogen Up 6%

    IBD
  9. Stocks Hold Near Session Highs; FedEx Bounces Back

    IBD
  10. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  11. United Therapeutics: Will It Pass Peers In 2015?

    IBD
  12. Lilly Upgraded On 2 Potential Blockbuster Drugs

    IBD
  13. The Biotech Stock With The Most Upside In 2015, According To ...

    Benzinga
  14. Pfizer Spreading Its Wings Into A New Domain Of Life Sciences

    GuruFocus
  15. 3 Biotech ETFs Rally On Merger News

    Benzinga
  16. Hot Drugmakers Build More Labs, Grab Space In Boston

    IBD
  17. Will New Alzheimer's Drug Boost Biogen?

    IBD
  18. Stock Market Today: Stocks Worsen Near Midday; Airlines Rally

    IBD
  19. Biogen's Alzheimer's Drug Moves to Phase III

    GuruFocus
  20. Stock Market Today: Indexes Close Near Day's Highs

    IBD
  21. Great News For Biogen, But What's Next For The Stock?

    Benzinga
  22. Biogen Drug Test Advances

    IBD
  23. Stock Market Today: Indexes Trade Near Session Highs

    IBD
  24. Deutsche Bank Sees More Upside For Biogen

    Benzinga
  25. Biogen Alzheimer's Drug Succeeding In Early Tests

    IBD
  26. Here's Why Biogen Shares Soared Today

    Benzinga
  27. Stock Market Today Opens Higher; FedEx, Biogen, Cypress Surge

    IBD
  28. Biogen Up Sharply On Promising Alzheimer's Results

    Benzinga
  29. Novartis' MS drug fails trial

    IBD
  30. Novartis' Gilenya Fails To Treat Progressive MS

    IBD
  31. FDA Orders New Label For Biogen Idec's MS Drug

    Benzinga
  32. UPDATE: Credit Suisse Reiterates On Biogen Idec On Gilenya PPMS ...

    Benzinga
  33. Biotech Stocks Hit: Stock Market To See New Leaders?

    IBD
  34. Stocks Drift Lower As Biotechs Tumble

    IBD
  35. Stocks Mixed; Amazon Jumps On Book Deal

    IBD
  36. The Bull/Bear Breakdown On Biogen Idec

    Benzinga
  37. Gilead Sciences Releases Impressive Results for Hepatitis C Drug

    GuruFocus
  38. Energy Stocks: Cash Metric Flashes “Oversold”

    YCharts
  39. Shire CEO Looks Ahead To Independent Future

    IBD
  40. Three Attractively Priced Small Cap Biotech Stocks

    GuruFocus
  41. These 5 Drugmakers' Earnings Excelled This Quarter

    IBD
  42. Citi, Jefferies Weigh In On Biogen Idec Amid Q3 Earnings

    Benzinga
  43. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  44. Leading Researchers Join Biogen Idec To Advance Drug Discovery ...

    Benzinga
  45. Better Biotechs Don't Satisfy

    IBD
  46. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD
  47. Markets Reverse Early Morning Gains Following Canadian Shooting

    Benzinga
  48. Major Indexes End Win Streak; Super Micro Surges

    IBD
  49. Stocks Erase Modest Gains; Apple Flirts With Breakout

    IBD
  50. Stocks Up at Midday; Super Micro Retakes Buy Point

    IBD
  51. Biogen, Thermo Reports Disappoint; Abbott Accelerates

    IBD
  52. Stocks Cling To Slender Advance; Boeing, Cree, Biogen Slide

    IBD
  53. Morning Market Losers

    Benzinga
  54. Benzinga's Top #PreMarket Losers

    Benzinga
  55. UPDATE: Biogen Idec Posts Upbeat Q3 Results, Raises Earnings ...

    Benzinga
  56. Earnings Scheduled For October 22, 2014

    Benzinga
  57. Biogen Leads 5 Top Biotech Stocks As Earnings Loom

    IBD
  58. Yahoo, Super Micro Rally After Hours

    IBD
  59. Celgene Reports More Good Crohn's Disease Data

    IBD
  60. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD
  61. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD
  62. Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals

    IBD
  63. IPO Stock Watch: Biotech Forward Pharma Falls On IPO

    IBD
  64. Major Averages Pare Losses, Then Head Lower Again

    IBD
  65. IBD 50: Medical, Internet Companies Top Q3 Estimates

    IBD
  66. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  67. Which Fund Has The Most To Gain From Biogen Idec?

    Benzinga
  68. IBD 50: Medical, Internet Companies Top Q3 Profit Estimates

    IBD
  69. Most Top Industry Groups Fall Harder Than Market

    IBD
  70. Biogen Idec Inc's Stock Is Set To Drop

    Benzinga
  71. Second Oldest Stock Fund Is As Nimble As A Teenager

    IBD
  72. Top Fund Buys: Chipotle, Allergan, Jazz, Gilead

    IBD
  73. Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20%

    GuruFocus
  74. Biogen Idec Inc Still Showing Relative Weakness Compared To Biotech ...

    Benzinga
  75. Biotech Stocks Rebound On Strong Earnings, New Drugs

    IBD
  76. Large-Cap Tech, Biotech Names Hang Tough In Shaky Market

    IBD
  77. New MS Drugs Offer Promise

    IBD
  78. Multiple Sclerosis Drugs Could Transform Market Again

    IBD
  79. Technology Stocks Slide But Other Sectors Hold Up Better

    IBD
  80. A Few Reasons Why AbbVie's Momentum Will Continue

    GuruFocus
  81. Stocks Get Hit Hard; GoPro, Skechers Buck Weakness

    IBD
  82. Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains

    IBD
  83. Apple Fuels Tech Sell-Off; Valeant Bucks The Trend

    IBD
  84. Stocks End Skid; Vertex, Alexion Lead Biotech Rebound

    IBD
  85. Stocks Up In Afternoon; Hasbro Jumps On Disney Deal

    IBD
  86. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD
  87. Stocks Hold Solid Gains; CyberArk Soars In Debut

    IBD
  88. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD
  89. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD
  90. 2 Columbia Growth Funds Notch Impressive Three-Month Performance

    Benzinga
  91. Nasdaq Falls Hard, But Apple Resilient On iPhone Orders

    IBD
  92. Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers

    IBD
  93. Why Nine of Fifteen Oil Majors Are Undervalued

    YCharts
  94. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  95. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD
  96. Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech ...

    Benzinga
  97. Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of ...

    Benzinga
  98. Biogen Announces Five-Year Results from ENDORSE Phase 3 Study ...

    Benzinga
  99. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD
  100. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD
Trading Center